Roth MKM analyst Scott Fortune resumed coverage of Bioceres with a Buy rating and $15 price target. With its comprehensive biological crop protection and nutrition portfolio and proprietary HB4 drought-resistant seed platform, the company is “well positioned,” contends the analyst, who expects a continuation of mid-teens organic growth and expanding AEBITDA margins to 25% amid growing global biological penetration of the ag input market.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX: